View Older Stories View More Recent Stories

Feb 6, 2017 06:58AM ISS Endorses Full Slate of venBio Nominees at Immunomedics
Feb 2, 2017 04:15PM Immunomedics Mails Letter to Stockholders Highlighting Strength of New Board and Deep Engagement in Robust, Value-Creating Strategic and CMC Processes
Feb 2, 2017 02:25PM OrbiMed Comments on Immunomedics Proxy Contest
Feb 1, 2017 02:22PM Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
Jan 30, 2017 05:02PM Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
Jan 30, 2017 09:00AM Immunomedics Sets the Record Straight in New Presentation
Jan 30, 2017 09:00AM venBio Calls on Immunomedics Stockholders to Support Meaningful Change
Jan 27, 2017 07:00AM Immunomedics Issues Statement to Stockholders and Files Investor Presentation
Jan 26, 2017 08:11AM Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
Jan 26, 2017 08:00AM venBio Releases Presentation Detailing Urgent Case for Change at Immunomedics
Jan 24, 2017 07:00AM Immunomedics Mails Letter to Stockholders
Jan 18, 2017 05:16PM Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
Jan 18, 2017 03:02PM venBio Sends Letter to Immunomedics Stockholders
Jan 12, 2017 07:00AM Immunomedics to Mail Letter to Stockholders Highlighting Unprecedented Progress Toward Enhanced Value Creation
Jan 11, 2017 05:09PM Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
Jan 11, 2017 09:25AM Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
Jan 11, 2017 09:00AM venBio Sends Letter to Immunomedics Stockholders
Jan 10, 2017 05:17PM Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
Jan 10, 2017 08:00AM venBio Responds to Immunomedics Announcement
Jan 9, 2017 06:00AM Immunomedics Announces Reconstituted Board of Directors and Leadership Succession Plan
Dec 6, 2016 05:02PM Form DEFC14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
Dec 2, 2016 05:30AM Impel NeuroPharma Announces $36M Funding to Advance Novel Drug Delivery Platform for Central Nervous System Disorders
Nov 29, 2016 04:11PM Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
Nov 29, 2016 03:41PM Form PRRN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
Nov 29, 2016 09:00AM venBio Responds to Immunomedics’ Postponement of Annual Meeting
Nov 28, 2016 07:03AM Immunomedics (IMMU) Announces Postponement of Annual Meeting of Stockholders
Nov 28, 2016 07:00AM Immunomedics Postpones 2016 Annual Meeting of Stockholders
Nov 22, 2016 03:08PM Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
Nov 22, 2016 09:00AM venBio Comments on its Recent Nomination of Four Highly-Qualified Candidates for Board of Immunomedics, Inc.
Nov 18, 2016 04:15PM Immunomedics Comments on Receipt of Director Nominations
Nov 16, 2016 03:48PM UPDATE: Immunomedics (IMMU) Shares Pop to Session Highs Following venBio 13D Filing
Nov 16, 2016 03:38PM Form SC 13D IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
Nov 16, 2016 03:30PM Form PREC14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
Nov 14, 2016 03:38PM Form 13F-HR venBio Select Advisor For: Sep 30
Oct 11, 2016 03:42PM Form D/A venBio Select Fund Ltd.
Oct 11, 2016 03:38PM Form D/A venBio Select Fund LLC
Aug 31, 2016 05:00AM Heart Metabolics Announces Initiation Of Phase 2b Study Of Perhexiline For Hypertrophic Cardiomyopathy
Aug 31, 2016 05:00AM Heart Metabolics Announces Initiation Of Phase 2b Study Of Perhexiline For Hypertrophic Cardiomyopathy
Aug 15, 2016 04:12PM Form 13F-HR venBio Select Advisor For: Jun 30
May 17, 2016 08:00AM Heart Metabolics Adds New Board Member And Expands Senior Management Team
May 16, 2016 04:31PM Form 13F-HR venBio Select Advisor For: Mar 31
May 6, 2016 07:30AM venBio Closes $315 Million Life Sciences Venture Capital Fund
Apr 29, 2016 05:47PM Form SC 13G Nabriva Therapeutics AG Filed by: venBio Global Strategic Fund II L.P.
Apr 20, 2016 01:05AM Checkmate Pharmaceuticals Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer and Announces Dosing of First Patient in Immuno-Oncology Phase 1b Trial with CMP-001, a TLR9 Agonist
Mar 15, 2016 08:00AM Heart Metabolics Announces Multiple Senior Appointments To Management Team
Feb 12, 2016 12:01PM Form 13F-HR venBio Select Advisor For: Dec 31
Feb 12, 2016 11:13AM Form SC 13G PERNIX THERAPEUTICS HOLD Filed by: venBio Select Advisor LLC
Feb 12, 2016 11:12AM Form SC 13G Mirati Therapeutics, Filed by: venBio Select Advisor LLC
Feb 12, 2016 11:11AM Form SC 13G Lion Biotechnologies, Filed by: venBio Select Advisor LLC
Feb 12, 2016 06:00AM Apellis Completes $47 Million Series D Financing
View More Recent Stories View Older Stories